While targeting the type IFN pathway has proven to be efficacious, further studies are warranted to determine how to select appropriate patient populations for precision medicine treatment of SLE, while at the same time considering the safety profiles and efficacy of existing and future IFN targeting modalities. The gene discussed is IFNA1; the disease is systemic lupus erythematosus.